Monograph Details
|
|
Ob/Gyn
> Infertility
|
|
REPRONEX 75 IU |
| Manufacturer |
|
Ferring Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Follicle-stimulating hormone 75 IU + luteinizing hormone 75 IU; per vial; pwd for SC or IM inj after reconstitution. |
| Also |
|
• REPRONEX 150 IU
|
| Indications |
|
Multiple follicular development for in vitro fertilization and ovulation induction in women who have previously received pituitary suppression. |
| Children |
|
Not applicable. |
| Adults |
|
For controlled ovarian hyperstimulation: 150 IU daily for 1st 5 days of treatment, followed by 5000–10000 Units of hCG 1 day after last dose. ART: Initially 225 IU followed by 5000–10000 Units of hCG. For both: Adjust in increments of 75–150 IU at intervals of at least 2 days; max 450 IU/day and 12 days treatment. |
| Contraindications |
|
Primary ovarian failure. Uncontrolled thyroid or adrenal dysfunction. Intracranial lesions. Undiagnosed abnormal vaginal bleeding. Ovarian cysts or enlargement. Pregnancy (Cat.X). |
| Precautions |
|
Be fully familiar with infertility treatment and its complications before using this product. Do complete gynecological and endocrinological exam first. Monitor appropriate lab values. May cause false (+) pregnancy test. Thromboembolic disorders. If ovaries are excessively enlarged on last day of therapy do not administer hCG; this decreases risk of ovarian hyperstimulation syndrome (OHSS). Discontinue if OHSS occurs. Nursing mothers. |
| Adverse Reactions |
|
OHSS with pulmonary and vascular complications, hemoperitoneum, adnexal torsion, ovarian enlargement or cysts, abdominal pain, flu-like symptoms, GI disturbances, local reactions, rash, dizziness, tachycardia, dyspnea, tachypnea, risk of high order multiple births. |
| How Supplied |
Vials 75 IU—1, 5
150 IU—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
